A-5784, titled “Requires pharmacist or pharmacist's designee to notify consumer of substituted drug or biological product,” would amend New Jersey’s 1977 drug-substitution law and 2015 biological-product law; it would not create a separate program. Its stated goal is to notify consumers when a pharmacist substitutes a product. The bill is introduced and is not law. The parent Acts were not supplied, so their current wording could not be independently checked.
No publicly available information on the bill’s cost.
Bills on related subjects, starting with New Jersey.
The bill would require the insurance commissioner to create one standard form for network providers seeking prescription drug coverage decisions, which payers must accept on paper or electronically.
Status
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Status
Introduced
Lawmakers would require health plans and Medicaid to cover 12-month refills of qualifying nonrefrigerated hormone therapy; Medicaid members would pay no cost-sharing.
Status
Introduced, Referred to Assembly Financial Institutions and Insurance Committee
Treasury would select a single pharmacy benefits manager by 2030 to run state health plans, require rebates pass through, and subject the manager to annual audits.
Status
Introduced, Referred to Assembly Financial Institutions and Insurance Committee